Le Lézard
Classified in: Health, Covid-19 virus
Subject: TRI

SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China

HONG KONG, May 17, 2022 /PRNewswire/ -- SIMCERE PHARMA (HK.2096)  announced that SIM0417, a candidate drug against SARS-Cov-2, for which the Company holds license from Shanghai Institute of Materia Medica (SIMM) and Wuhan Institute of Virology, Chinese Academy of Sciences, has obtained the Clinical Trial Approval issued by the National Medical Products Administration  in China, and is proposed for post-exposure prophylaxis for close contacts of individuals who test positive for SARS-CoV-2.


SIM0417 (molecule serial number SSD8432) targets 3CL protease, which is a key protease required for SARS-CoV-2 replication. It is currently under clinical development for SARS-CoV-2 infected patients. SIM0417 has shown broad-spectrum antiviral activity, good in vivo pharmacokinetic properties, and safety in pre-clinical studies. It is a highly active, low toxicity, orally administrable small molecule anti-SARS-CoV-2 drug candidate.


Simcere Pharmaceutical Group is an innovation and R&D-driven pharmaceutical company. It has established a National Key Laboratory of Translational Medicine and Innovative Drug Development. The company focuses on three therapeutic areas, oncology, central nervous system and autoimmune diseases, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "providing today's patients with medicines of the future." Leveraging its R&D capability and commercialization excellence, Simcere has built a market-leading product portfolio in China. Its vigorous in-house R&D efforts and extensive R&D collaborations have made it a strategic cooperation partner with world leading innovative companies and research institutes.

SOURCE Simcere

These press releases may also interest you

at 08:35
Worldwide Clinical Trials, Inc., (Worldwide) the industry's leading global, midsize, full-service contract research organization (CRO), has been recognized for excellence and honored in five categories in the 2022 CRO Leadership Awards, based on...

at 08:35
FSD Pharma Inc. (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the results of its annual general meeting of shareholders ("AGM"), held...

at 08:35
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as Chief Scientific...

at 08:30
NeuroSense Therapeutics Ltd. ("NeuroSense"), a company developing treatments...

at 08:30
MAPS Public Benefit...

at 08:30
While circulating cell-free...

News published on 17 may 2022 at 23:41 and distributed by: